Fig. 2From: Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomesMedian percentage changes from baseline in biomarkers through week 24. Median percentage changes from baseline in biomarkers of a, b the acute-phase response (CRP and SAA), c–f bone remodelling (P1NP, OC, total RANKL and OPG), g synovial inflammation (MMP-3) and h atherothrombosis (Lp [a]). *Adjusted p < 0.05; **adjusted p < 0.01 vs. adalimumab; ***adjusted p < 0.0001 vs. adalimumab (Benjamini–Hochberg procedure). CRP, C-reactive protein; Lp(a), lipoprotein (a); MMP-3, matrix metalloproteinase-3; OC, osteocalcin; OPG, osteoprotegerin; P1NP, procollagen type 1 N-terminal propeptide; Q, quartile; q2w, every 2 weeks; RANKL, receptor activator of nuclear factor-κB ligand; SAA, serum amyloid ABack to article page